Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Kumar, Anupam ^a   Xu, Jia ^a,b   Brady, Samuel ^a,b   Gao, Hui ^a   Yu, Dihua ^a,b   Reuben, James ^a   Mehta, Kapil ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; FIBRONECTIN; HERMES ANTIGEN; NERVE CELL ADHESION MOLECULE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SNAIL1; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ARTICLE; BREAST EPITHELIUM; CELL DIFFERENTIATION; CELL DISRUPTION; CELL GROWTH; CELL INVASION; CELL POLARITY; CELL POPULATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; CYTOLOGY; ENZYMOLOGY; MAMMARY GLAND; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GTP-BINDING PROTEINS; HUMANS; MAMMARY GLANDS, HUMAN; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSGLUTAMINASES;

EID: 78149462058     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013390     Document Type: Article

References (50)

1. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205: 275-292.
2. Mehta K, Fok J, Miller FR, Koul D, Sahin AA (2004) Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10: 8068-8076.
3. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K (2007) Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 26: 2459-2470.
4. Lorand L, Graham RM (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4: 140-156.
5. Im MJ, Russell MA, Feng JF (1997) Transglutaminase II: a new class of GTPbinding protein with new biological functions. Cell Signal 9: 477-482.
6. Chandrashekar R, Tsuji N, Morales T, Ozols V, Mehta K (1999) An ERp60- like protein from the filarial parasite Dirofilaria immitis has both transglutaminase and protein disulfide isomerase activity. Proc Natl Acad Sci USA 95: 531-536.
7. Mishra S, Murphy LJ (2004) Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factorbinding protein-3 kinase. J Biol Chem 279: 23863-23868.
8. Telci D, Collighan RJ, Basaga H, Griffin M (2009) Increased TG2 expression can result in induction of transforming growth factor beta1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide. J Biol Chem 284: 29547-29558.
9. Fesus L, Piacentini M (2002) Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27: 534-539.
10. Verma A, Guha S, Wang H, Fok JY, Koul D, et al. (2008) Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res 14: 1997-2005.
11. Satpathy M, Shao M, Emerson R, Donner DB, Matei D (2009) Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J Biol Chem 284: 15390-15399.
12. Zemskov EA, Loukinova E, Mikhailenko I, Coleman RA, Strickland DK, et al. (2009) Regulation of platelet-derived growth factor receptor function by integrinassociated cell surface transglutaminase. J Biol Chem 284: 16693-16703.
13. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, et al. (2006) Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res 66: 8788-8795.
14. Balklava Z, Verderio E, Collighan R, Gross S, Adams J, et al. (2002) Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but is important for its secretion. J Biol Chem 277: 16567-16575.
15. Micalizzi DS, Ford HL (2009) Epithelial-mesenchymal transition in development and cancer. Future Oncol 5: 1129-1143.
16. Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829.
17. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
18. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, et al. (2009) Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-2407.
19. Herman JF, Mangala LS, Mehta K (2006) Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25: 3049-3058.
20. Kalluri R (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119: 1417-1419.
21. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
22. Cifone MA, Fidler IJ (1980) Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci USA 77: 1039-1043.
23. Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268.
24. Xu J, Lamouille S, Derynck R (2009) TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172.
25. Tse JC, Kalluri R (2007) Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101: 816-829.
26. Kim DS, Park SS, Nam BH, Kim IH, Kim SY (2006) Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66: 10936-10943.
27. Kim Y, Eom S, Kim K, Lee YS, Choe J, et al. (2010) Transglutaminase II interacts with rac1, regulates production of reactive oxygen species, expression of snail, secretion of Th2 cytokines and mediates in vitro and in vivo allergic inflammation. Mol Immunol 47: 1010-1022.
28. Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, et al. (2008) Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 11: 123-151.
29. Jung SA, Lee HK, Yoon JS, Kim SJ, Kim CY, et al. (2007) Upregulation of TGF-beta-induced tissue transglutaminase expression by PI3K-Akt pathway activation in human subconjunctival fibroblasts. Invest Ophthalmol Vis Sci 48: 1952-1958.
30. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
31. Liao MJ, Zhang CC, Zhou B, Zimonjic DB, Mani SA, et al. (2007) Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res 67: 8131-8138.
32. Kotsakis P, Griffin M (2007) Tissue transglutaminase in tumour progression: friend or foe? Amino Acids 33: 373-384.
33. Chhabra A, Verma A, Mehta K (2009) Tissue transglutaminase promotes or suppresses tumors depending on cell context. Anticancer Res 29: 1909-20.
34. Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, et al. (2008) Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 29: 1893-1900.
35. Verma A, Mehta K (2007) Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 10: 144-151.
36. Ai L, Kim W-J, Demircan B, et al. (2008) The transglutaminase 2 gene, a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 29: 510-518.
37. Siegel M, Strnad P, Watts RE, Choi K, Jabri B, Omary MB, Khosla C (2008) Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS ONE 3: e1861.
38. Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, et al. (2009) Epithelial-tomesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 69: 9192-9201.
39. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
40. Chen WC, Obrink B (1991) Cell-cell contacts mediated by E-cadherin (uvomorulin) restrict invasive behavior of L-cells. J Cell Biol 114: 319-327.
41. Verderio EA, Telci D, Okoye A, Melino G, Griffin M (2003) A novel RGDindependent cell adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis. J Biol Chem 278: 42604-42614.
42. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, et al. (2004) NF-kB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114: 569-581.
43. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2: 301-310.
44. Parsad S, Ravindran J, Aggarwal BB (2010) NF-kB and cancer: how intimate is this relationship. Mol Cell Biochem 336: 25-37.
45. Orlowski RZ, Baldwin Jr. AS (2002) NF-kB as a therapeutic target in cancer. Trends Mol Med 8: 385-389.
46. Wu Y, Deng J, Rychahou PG, Qui S, Evers BM, Zhou BP (2009) Stabilization of Sanil by NF-kB is required for inflammation-induced cell migration and invasion. Cell 15: 416-28.
47. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshat (2007) NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26: 711-724.
48. Quan G, Choi JY, Lee DS, Lee SC (2005) TGF-beta1 upregulates transglutaminase 2 and fibronectin in dermal fibroblasts: a possible mechanism for the stabilization of tissue inflammation. Arch Dermatol Res 297: 84-90.
49. Ritter SJ, Davies PJ (1998) Identification of a transforming growth factor-beta1/ bone morphogenetic protein 4 (TGF-beta1/BMP4) response element within the mouse tissue transglutaminase gene promoter. J Biol Chem 273: 12798-12806.
50. Nunes I, Gleizes PE, Metz CN, Rifkin DB (1997) Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 136: 1151-1163.